Aardvark Therapeutics, Inc. (NASDAQ:AARD) CEO Buys $264,672.00 in Stock

Aardvark Therapeutics, Inc. (NASDAQ:AARD) CEO Tien-Li Lee acquired 16,542 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The stock was bought at an average cost of $16.00 per share, for a total transaction of $264,672.00. Following the completion of the transaction, the chief executive officer now directly owns 1,496,175 shares in the company, valued at $23,938,800. This represents a 1.12 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Aardvark Therapeutics Trading Up 15.8 %

AARD opened at $17.25 on Friday. Aardvark Therapeutics, Inc. has a 1 year low of $11.55 and a 1 year high of $19.58.

Aardvark Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.